- With The RNAi Sector Heating Up Again This Is Now The Undervalued Biotech Stock To Watch
- Explosion At Neptune's Manufacturing Facility Leaves Shares Halted
- Taking Note Of IntelliPharmaCeutics' Now Imminent FDA Decision
- AVEO Management Excited About Statistically Significant Improvement Shown In Phase III TIVO-1 Trial
- Neptune's Dividend Catalyst Finally In Play
M. E. Garza
M. E. Garza
Send Message
M. E. Garza
Stop FollowingM. E. Garza
ABOUT
M.E. Garza is one of the founders of the biotech and healthcare sector news portal BioMedReports.com. He believes in getting the news from credible sources on the street and often reaches out to CEOs and newsmakers directly for interviews and discussions about their companies. Since he began publishing in 2008, Garza has built a reputation as a writer and reporter who can move markets. His track record for accurately reporting rumors and alerting readers about developments in the biotech/healthcare sector is unmatched during that time.
SNAPSHOT
- Description: Newsletter author. Trading frequency: Daily
- Interests: Stocks - long, Tech stocks
COMPANY
BioMedReports.Com BioMedReports.com, designed by and for investors and traders, is a full news portal offering unbiased bio stock reporting and analysis about emerging biotech companies, offering FDA and clinical trial calendars and valuable industry and stock market information.
BLOG
Daily Info Feeds and Updates
I don't keep a blog, but I often update our readers via twitter and our premium subscribers can often find my reporter's notes on stories and stocks that I will be covering in upcoming days.
For more information on getting that information go here:
http://biomedreports.com/only-premium-access.html
For more information on getting that information go here:
http://biomedreports.com/only-premium-access.html
Book
Currently, there are no book details for M. E. Garza.
LATEST STOCKTALK
more »
Hearing some interesting developments on the horizon for $NWBO. Did an article on them yesterday. Looks promising. http://bit.ly/NWBOnews
Jul 12, 2011
Latest Comments
more »
- Awesome work as always David! on Resistance (To Resistance) Is Futile: The Growi...
- Canaccord Genuity biotechno... on Amarin Announces Submission of Supplemental New...
- $PSTI is really a no-braine... on Maxim Group Highlights 3 Stem Cell Stocks To Co...
- Fact is, the company is in ... on Let's Watch Amarin Get Crushed By Wall Street
- PSTI will certainly move on... on Dilution Is The Solution To Pollution
Latest comments on M. E.'s Articles
- PPHMstockofcentury on Trial News Make Peregrine Pharmaceuticals Worth...
- Jason Boyce on With The RNAi Sector Heating Up Again This Is N...
- Scott Matusow on Closer Look: BioLineRx Snags Another Hep-C Lice...
- mopar44o on Taking Note Of IntelliPharmaCeutics' Now Immine...
- Michael Webb on Is The Novavax 'New Paradigm' Worth A Second Look?
LATEST ARTICLES & INSTAPOSTS
more »


